All times are listed in CEST (Central European Summer Time)
Found 1 Presentation For Request "1322p"
1322P - Real-world treatment patterns and immunotherapy (IO) sequencing based on PD-L1 TPS in European patients with metastatic NSCLC
- Erin Janowicz (Wilmington, United States of America)
Abstract
Background
We evaluated a large real-world dataset for use of IO and chemotherapy (chemo) in clinical practice during a time of evolving treatment landscape in metastatic non-small cell lung cancer (NSCLC), based on PD-L1 tumor proportion score (TPS) in patients from the UK, Germany, France, Italy and Spain.
Methods
De-identified patient data collected from Q3/2018 to Q3/2019 were analyzed. Physicians completed the online data collection form in the Medimix LiveTracker™ based on their patients’ medical records. Patients with metastatic NSCLC without
Results
Of 5,415 patients receiving 1L treatment, 84% of NSCLC tumors were tested for PD-L1 expression. 1L chemo to 2L IO was prescribed to 71% and 84% of patients with PD-L1 TPS <1% and 1-49%, respectively (Table). Patients with PD-L1 TPS ≥50% primarily received IO alone followed by 2L chemo (58%), but 17% received 1L chemo followed by 2L IO. Comparing Q3/2018 versus Q3/2019 1L prescribing, use of IO plus chemo increased from 1% to 17% and 4% to 28% in patients with PD-L1 TPS <1% and 1-49%, respectively. In Q3/2019, no patient with PD-L1 TPS ≥50% received chemo alone compared to 6% a year earlier. Pembrolizumab was the most widely prescribed 1L checkpoint inhibitor, used in 95% of patients receiving IO. In 2L, nivolumab (54%), atezolizumab (23%) and pembrolizumab (23%) were used 1L and 2L selection and sequence, by PD-L1 TPS
PD-L1 TPS < 1% 1-49% ≥ 50% 68 68 68 73 71 71 IO alone, % 1 5 80 IO+chemo, % 3 8 5 Chemo alone, % 93 84 12 IO alone, % 72 88 28 IO+chemo, % 0.4 2 2 Chemo alone, % 23 9 64 1L chemo→2L IO, % 71 84 17 1L IO→2L chemo, % 0.6 2 58 1L IO→2L IO, % 0.4 1 8 1L chemo→2L chemo, % 21 4 2 IO alone, % 0.4 2 91 IO+chemo, % 1 4 1 Chemo alone, % 95 92 6 IO alone, % 5 6 84 IO+chemo, % 17 28 13 Chemo alone, % 76 62 0
Conclusions
1L and 2L prescribing patterns reflect adherence and adaptation to the emerging clinical trial data and practice guidelines. Our data suggests a clinically significant increase in prescribing IO with or without chemo as 1L treatment in Q3/2019, corresponding with the most recent guideline recommendations.
Legal entity responsible for the study
Medimix International.
Funding
Medimix International and PPD, LLC.
Disclosure
E. Janowicz, D. Anderson, N. Stoyanov, A. Combest: Full/Part-time employment: PPD. B. Nguyen: Shareholder/Stockholder/Stock options, Full/Part-time employment: PPD. All other authors have declared no conflicts of interest.